Meeting
2016 Genitourinary Cancers Symposium
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC): Cost of care for Medicare and commercially insured men.
Authors
Andrew J. Armstrong
Duke Cancer Institute, Duke University and the Department of Defense Prostate Cancer Clinical Trials Consortium, Durham, NC
Andrew J. Armstrong , Cat N Bui , Kate Fitch , Tia Sawhney , Bruce Brown , Scott C Flanders , Peter St. John Francis , Mark A. Balk , Julie Deangelis , James Chambers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 262)
DOI
10.1200/jco.2016.34.2_suppl.262
Abstract #
262
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth
Poster
2024 ASCO Genitourinary Cancers Symposium
Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
First Author: Peter C.C. Fong